The global tissue engineering market size was accounted at USD 11.81 billion in 2022 and it is expected to hit around USD 33.38 billion by 2032, expanding at a CAGR of 11% during the forecast period 2023 to 2032.
To regenerate, preserve, augment, or replace different kinds of biological tissues, the biomedical engineering field of tissue engineering combines cells with engineering, material technologies, and the proper biochemical and physicochemical parameters. To repair, replace, or regenerate tissues or organs, tissue engineering (TE), a fast-developing field, transforms basic knowledge in physics, chemistry, and biology into useful materials, technologies, and therapeutic approaches.
Assisting with tissues or organ regeneration, including bone healing (calcified tissue), heart tissue, cartilage tissue, vascular tissue, and pancreatic tissue are some of the main purposes of tissue engineering in medicine and research. The behaviour of stem cells is another topic of study in this area. Stem cells may differentiate into a wide variety of cell types and aid in the body's healing processes. The 3D aspect of tissue engineering enables a more in-depth examination of tumour architecture. Additionally, it offers a setting in which to test possible novel treatments for various disorders. It is anticipated that an increase in R&D efforts would help the market expand as awareness of tissue engineering rises in emerging economies.
The global market for tissue engineering is growing because of developed countries adopting regenerative medicine and tissue engineering technology. To have an advantage over rivals, key actors are forming alliances and working together.
Additionally, to fulfil the demand, prominent companies are upgrading their product portfolios and developing fresh tissue engineering products.
The healthcare sector has been significantly impacted by the COVID-19 epidemic. Since the COVID 19 pandemic, clinical tissue engineering research has been discontinued and non-COVID 19 clinical studies have been scaled back. In the meanwhile, a number of pharmaceutical and biotech companies have moved their attention to the creation of COVID-19 therapy medications and vaccines. Additionally, the global tissue engineering industry has been constrained by a significant decline in cell and tissue donation programmes. As a result, the worldwide tissue engineering industry is being constrained by delays and disruptions in clinical research as well as cancellations or delays in tissue replacement and reconstructive treatments.
Another element raising awareness is the growth in popularity of tissue regeneration technology due to effective products and lower rejection rates. Additionally, there are more procedures performed for regeneration. Pre-clinical research is being done on the use of tissue-engineered vascular grafts in cardiovascular surgery and therapy. Currently, bladders made of tissue engineering are being successfully transplanted outside of the patient's body.
Report Scope of the Tissue Engineering Market
|Market Size in 2023||
USD 13.05 Billion
|Market Size by 2032||
USD 33.38 Billion
|Growth Rate from 2023 to 2032||CAGR of 11%|
|Forecast Period||2023 to 2032|
|Segments Covered||Application, Material Type, End-Use, and Geography|
|Companies Mentioned||Stryker Corporation, Organogenesis Inc., Cook Biotech Inc., Integra Life Sciences Corporation, 3M, AbbVie Inc., Medtronic, Zimmer Biomet, Baxter International Inc., DePuy Synthes (Johnson & Johnson Services, Inc.), B. Braun Melsungen AG|
Key Market Drivers
Key Market Challenges
Multiple problems associated with tissue engineering
Key Market Opportunities
Increasing demand for regenerative medicine
Technological advancements in tissue engineering
Due to the growth in musculoskeletal problems, the orthopaedics, musculoskeletal, and spine segments led the tissue engineering market in 2022. The spine, bone replacements, and bone transplants are all part of the orthopaedic regeneration section. Around 900,000 surgical procedures each year include bone replacement or repair, according to the Medicare and Medicaid programme in the United States. Due to an annual occurrence of almost 15 million fracture cases, the cost of healthcare in the US rises by USD 59.9 billion.
Due to a sharp rise in the frequency of cardiovascular illnesses throughout the world, the sector for cardiology and vascular tissue engineering is predicted to develop at the greatest pace during the analysis period. In order to heal, restore, and re-vascularize the injured cardiac tissues, important actors are also participating in the development of stem cell treatments. Additionally, research is being done on gene therapy, sophisticated biologics, and small chemicals to promote the regeneration of injured cardiac cells. In order to examine the impact of cardiovascular illnesses, single and mixed cells from autologous and allogeneic stem cells are being used more often. Additionally, segment growth is anticipated to be boosted by developments in tissue engineering technology. For instance, the creation of 3D heart muscles and Engineered Heart Tissue (EHT) would open up prospective markets for the expansion of tissue engineering in the future.
Material Type Insights
The market leader in 2022 is anticipated to be the sector of biologically generated materials. The development of tissue engineering and biomedical devices that naturally boost the ability of tissues to regenerate in order to repair deteriorated bodily mechanisms heavily relies on biomaterials.
Neo-tissues that are similar to their basic body components are produced in vitro using biologically derived ingredients. Additionally, these materials promote tissue regeneration by the targeted delivery and on-demand release of certain chemokines at damage sites, as well as by providing transient, tissue-like support matrices that degrade naturally and function. However, throughout the anticipated period, the synthetic material category is expected to see the greatest CAGR in the worldwide tissue engineering market.
Tissue Engineering Market Share, By Region, 2022 (%)
|Regions||Revenue Share in 2022 (%)|
Due to an increase in interest in stem cell treatment and a rising elderly population, North America had the greatest revenue share in 2022. Additionally, the availability of private and public financing, high healthcare spending, and sophisticated technology for the diagnosis and treatment of chronic conditions encourage a higher proportion of the regional market for tissue engineering. Due to the availability of public funding as well as considerable investments made by private groups, the U.S. is thought to account for a sizeable portion of global revenue. The "2020: A New Vision" effort was started by the U.S. Department of Health to put stem cell treatment and regenerative medicine at the forefront of healthcare. Technology innovation and translational advancement depend critically on the transformational effects of employing regenerative medicine in clinical settings.
Over the course of the projected period, Asia Pacific is anticipated to develop at the quickest CAGR. One of the top nations promoting technical advancements in the field of tissue engineering is Japan. Additionally, it is anticipated that the market for tissue engineering in Asia would develop because of an increase in the frequency of clinical illnesses like cancer. Growth in the industry is also fueled by elements like the development of 3D bioprinting and medical tourism in the area.
Japan is a desirable tissue engineering outsourcing market for wealthy countries like the U.S. Additionally encouraging for quicker clearance of clinical trials is its regulatory framework. The Regenerative Medicine Law, which permits the adoption of practises that might hasten the clinical development of regenerative and cell-based therapies, has been authorised by the Ministry of Health, Labor, and Welfare (MHLW).
Segments Covered in the Report
By Material Type
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client